Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efsubaglutide Alfa in Overweight and Obese Subjects
NCT06921486Phase 3Active, not recruiting
- Sponsor
- Shanghai Innogen Pharmaceutical Technology Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of efsubaglutide alfa in obesity, Overweight, sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd.. Started Mar 2025; status: active, not recruiting.
02
Drugs
efsubaglutide alfa
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06921486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06921486.